Network enewsletter issue 2 January 2019

Sign up to receive 'Network' – our alumni newsletter!

We are excited to announce our new alumni newsletter 'Network' – an e-newsletter to help us keep in touch with our alumni in order to share exciting news and updates about the ICR.

Subscribe

We would love for past students to continue to feel part of our community even after you’ve moved on in your career. We hope that you are as proud of us as we are of you!

Sign up for our twice-yearly newsletter to:

keep up-to-date on the ICR’s key achievements.

hear about any new strategic initiatives.

learn about the latest events or collaboration opportunities 

Subscribe to Network

You can unsubscribe from this email at any time. See our privacy policy for more details on how we manage information.

Keep in touch!

We’d love to hear from you – you can email us at [email protected] to have your story featured on our website on our alumni profiles page.

We also want to encourage networking opportunities between our current students and past alumni – please join our ICR student alumni LinkedIn group.

We are very enthusiastic about what’s to come for the ICR and look forward to sharing our achievements with you!

Previous newsletters

You can view our previous newsletters online:

Network issue #5 – September 2020

Network issue #4 – January/February 2020

Network issue #3 – July 2019

Network issue #2 – January 2019

Network issue #1 – July 2018

Latest ICR News

Silencing gene may combat formation of radiation-induced scar tissue, a new study reveals

04/06/25

A new study suggests that silencing CXCL12, a gene involved in tissue scarring and repair, could help reduce the formation of scar tissue that can caused by radiotherapy. Ultimately, the researchers hope this approach could improve treatment outcomes for breast cancer patients undergoing radiotherapy and reconstructive surgery.
See full story
ASCO 2025: One-time cell therapy offers long-term survival hope for patients with advanced melanoma

02/06/25

A one-time immunotherapy treatment using a patient’s own immune cells has shown long-lasting benefit for people with advanced melanoma, a serious form of skin cancer, according to new five-year follow-up data from a pivotal clinical trial.
See full story
ASCO 2025: Next-generation breast cancer drug targets tumours before they have a chance to grow

01/06/25

A powerful new drug for advanced breast cancer can be used to treat emerging tumours, months before they have a chance to grow, helping to keep patients well for longer and delaying the need for later-line therapies including chemotherapy. Results of a global study, funded by AstraZeneca and co-led by researchers at The Institute of Cancer Research, London, The Royal Marsden NHS Foundation Trust and Institut Curie, Paris, were presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on 1 June 2025.
See full story
Professor Nick Turner (right) in his lab at the Institute of Cancer Research, London
ASCO 2025: New therapy improves survival in advanced breast cancer and delays need for chemotherapy

31/05/25

A promising new therapy can help patients with aggressive advanced breast cancer live longer and delays the need for further chemotherapy, new research has shown. Final results of the INAVO120 study, led by an international team of researchers including scientists at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, have demonstrated the potential of the new therapy combination for targeting PIK3CA-mutated hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer – a common form of the disease.
See full story